{{scheme.chgp}}%
{{scheme.chgp}}%
No Matches Found
{{scheme.chgp}}%
No Matches Found
No Matches Found
Amneal Pharmaceuticals, Inc.
Amneal Pharmaceuticals Experiences Revision in Stock Evaluation Amid Strong Market Performance
Amneal Pharmaceuticals, Inc. has recently revised its evaluation amid changing market conditions. The company’s stock price has shown resilience, with a notable year-to-date return of 33.21%. Over the past year, it has outperformed the S&P 500, reflecting its strong recovery and growth trajectory in the pharmaceuticals sector.
Is Amneal Pharmaceuticals, Inc. technically bullish or bearish?
As of October 3, 2025, Amneal Pharmaceuticals shows a bullish technical trend supported by positive MACD and Bollinger Bands, despite some short-term weakness indicated by the weekly RSI, and has significantly outperformed the S&P 500 over three years.
Amneal Pharmaceuticals Hits New 52-Week High of $10.67
Amneal Pharmaceuticals, Inc. achieved a new 52-week high of USD 10.67 on October 3, 2025, reflecting a 51.68% growth over the past year. The company, with a market capitalization of USD 3,056 million, faces challenges such as negative return on equity and a significant debt-to-equity ratio.
Is Amneal Pharmaceuticals, Inc. technically bullish or bearish?
As of October 3, 2025, Amneal Pharmaceuticals has a bullish technical trend, supported by positive MACD and Bollinger Bands signals, despite a bearish weekly RSI, and has significantly outperformed the S&P 500 with a year-to-date return of 31.19% compared to 14.18%.
Amneal Pharmaceuticals Hits New 52-Week High of $10.43
Amneal Pharmaceuticals, Inc. achieved a new 52-week high of USD 10.43 on October 1, 2025, reflecting a significant increase from its previous low. The company has seen a 51.53% rise in stock price over the past year, outperforming the S&P 500, and has a market capitalization of USD 3,056 million.
Is Amneal Pharmaceuticals, Inc. technically bullish or bearish?
As of September 5, 2025, Amneal Pharmaceuticals, Inc. shows a bullish technical trend, supported by positive daily moving averages and a weekly MACD, despite some caution from mildly bearish monthly indicators, while outperforming the S&P 500 with a year-to-date return of 23.86%.
Is Amneal Pharmaceuticals, Inc. overvalued or undervalued?
As of March 1, 2024, Amneal Pharmaceuticals, Inc. is considered a risky investment due to its high P/E ratio of 51.39, overvaluation compared to industry peers, and recent stock volatility despite a year-to-date return of 23.86%.
Is Amneal Pharmaceuticals, Inc. technically bullish or bearish?
As of June 6, 2025, the trend is mildly bearish, influenced by daily moving averages and monthly indicators, despite some bullish signals from the weekly MACD and RSI, indicating a cautious outlook.
What does Amneal Pharmaceuticals, Inc. do?
Amneal Pharmaceuticals, Inc. is a small-cap company in the Pharmaceuticals & Biotechnology industry. It currently has no dividend yield, and its financial metrics indicate significant negative values for debt equity and return on equity.
{{list.post_title}}
{{list.post_excerpt}}
{{list.post_title}}
{{list.post_excerpt}}
